Rasagiline

REFERENCES
and further reading

• 2009 ADAGIO study
• Adjunctive therapy/rasagiline in PD
• Agilect/Azilect monotherapy
• Ageing/dopaminergic cell death
• Anti-ageing?
• Anti-Alzheimer's neuroprotectants
• Anti-apoptotic activity
• Anti-apoptotic mechanisms
• Antidepressant cognitive enhancers?
• Antioxidant stategies/ageing
• Azilect/USA license
• Azilect/EU license
• Azilect/MAOIs
• Azilect/Parkinson's disease
• Azilect Prescribing Information (PDF)
• Bcl-2 gene family/apoptosis
• BDNF
• Cardiovascular effects
• Cerebellar granule cells
• Clinical trials
• Closed head injury
• Cognition/locomotion
• Cognitive enhancement
• Comparison with selegiline
• Cost-utility in advanced PD
• Dopamine
• Dopamine agonists/PD
• Dopaminergic cell death
• Drug development
• Dual AChE / MAO inhibitors
• Early Parkinson's disease
• Early-stage PD/Agilect
• Familial amyotrophic lateral sclerosis
• 'Freezing' gait
• GAPDH
• Genomics/proteomics
• Gait/rasagiline effects
• Gait
• Hypersexual effect
• Idiopathic Parkinson's disease
• Intracellular signalling pathways
• Irreversibile MAO-B inhibition
• Ischemia
• Ischemic protection
• Ladostigil (TV3326)
• Ladostigil: structure
• LARGO study
• Levodopa/dopamine
• Levodopa/noradrenaline
• Levodopa/rasagiline
• MAO
• MAO-B
• MAOI/MPTP
• MAOIs
• MAOIs/Parkinson's disease
• MAO inactivation
• MAP kinase / ChE inhibitors
• Memory and learning
• Metabolites
• Methodological worries
• Mitochondria
• Molecular mechanisms
• Monoamines
• Monoamine oxidase-B inhibition
• Motor function
• Motor fluctuations
• Multiple mechanisms
• Neuronal survival
• Neuropharmacology
• Neuroprotection
• Neuroprotective mechanisms
• Neurotrophic factors
• Noradrenaline
• Once-daily Azilect
• Oxygen-glucose deprivation/neuroprotection
• Parkinson's disease
• Parkinson's disease/Agilect
• Parkinson's disease, early
• Parkinson's disease/MAOI-b
• Parkinson's disease, neuroprotection
• Parkinson's disease, new drugs
• Parkinson's disease, prosurvival genes
• Parkinson's disease, rats
• Parkinson's disease/rasagiline
• Parkinson's disease/treatments
• 2-phenylethylamine (PEA)
• Pharmacokinetics/pharmacodynamics
• PRESTO study
• Propargylamine derivatives/MAO
• Propargylamine moiety/neuroprotection
• Propargylamines/anti-apoptosis
• Protein kinase C regulation
• Rasagiline: review
• Rasagiline (Agilect, Azilect)
• Rasagiline, clinical trials
• Rasagiline/ischaemia
• Rasagiline/neuron regeneration
• Rasagiline dosage/MAO inhibition
• Rasagiline monotherapy
• Rasagiline/neuroprotective effect
• Rasagiline/ Parkinson's disease
• Rasagiline pharmacology
• Rasagiline (Azilect): review
• Rasagiline: structure
• Rasagiline vs selegiline
• Rasagiline/self-image and sexuality
• Scepticism
• Rats/rasagiline/serotonergics
• Selegiline vs rasagiline
• SOD/CAT antioxidant activity
• Stroke prevention and recovery
• Substantia nigra/dopamine
• TV3326 (ladostigil)
• Tyramine challenge
• Tyramine/rasagiline
  
• Tyramine/MAOIs
• Tyrosine kinase activation
• VK-28
• Youdim, Professor M.

    

Suggested additions/updates?
E-mail: dave@bltc.com

Hotlinks
Parkinson's Disease